Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056599 · ClinicalTrials.gov registry record · Phase 1
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
A Phase 1 study, sponsored by Presage Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03056599 is a Phase 1 study that has completed, run by Presage Biosciences. The registered enrollment target is 23 participants.
The verdict
NCT03056599, a Phase 1 study, has completed, sponsored by Presage Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
Interventions
- DRUG Multiple drug microinjection
- DEVICE CIVO device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056599
The ClinicalTrials.gov registry entry for NCT03056599 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presage Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Multiple drug microinjection is the first listed.
NCT03056599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056599 about?
NCT03056599 is a clinical study titled "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma". This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
What is the current status of trial NCT03056599?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-12-15. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT03056599?
The interventions under investigation include: Multiple drug microinjection (DRUG), CIVO device (DEVICE).
Who is sponsoring clinical trial NCT03056599?
This trial is sponsored by Presage Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.